Hepatocellular carcinoma
By J. Llovet, Andrew K. Burroughs, Jordi Bruix1 , 2. The Lancet, 2003
717 citations recorded by the source corpus.
Hepatocellular carcinoma (HCC) is the fifth most common cause of cancer, and its incidence is increasing worldwide because of the dissemination of hepatitis B and C virus infection. Patients with cirrhosis are at the highest risk and should be monitored every 6 months. Surveillance can lead to diagnosis at early stages, when the tumour might be curable by resection, liver transplantation, or percutaneous treatment. In the West and Japan, these treatments can be applied to 30% of patients, and result in 5-year survival rates higher than 50%. Resection is indicated among patients who have one tumour and well-preserved liver function. Liver transplantation benefits patients who have decompensated cirrhosis and one tumour smaller than 5 cm or three nodules smaller than 3 cm, but donor shortage greatly limits its applicability. This difficulty might be overcome by living donation. Most HCC patients are diagnosed at advanced stages and receive palliative treatments, which have been assessed in the setting of 63 randomised controlled trials during the past 25 years. Meta-analysis shows that only chemoembolisation improves survival in well-selected patients with unresectable HCC.
Subfields: Epidemiology, Hepatology, Surgery
View Paper: https://www.semanticscholar.org/paper/d5dedba3da3e07f9c8943c0a5e9d4f55a68e70dd
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Epidemiology
In Hepatology
In Surgery
Citations in the corpus
- Novel prognostic marker PRMT1 regulates cell growth via downregulation of CDKN1A in HCC (2017, background): “Chronic hepatitis B and C virus (HBV and HCV, respectively) infections are important causes of HCC; alcohol, exposure to aflatoxin and diabetes are other factors in HCC pathogenesis [1, 2].”
- Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005. (2009, background): “blood supply, is reported to improve survival in well-selected patients with unresectable HCC.(8)”